Symbols / BNR Stock $7.73 +6.62% Burning Rock Biotech Limited

Healthcare • Diagnostics & Research • China • NGM
BNR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. Yusheng Han
Exch · Country NGM · China
Market Cap 81.52M
Enterprise Value -318.87M
Income -59.32M
Sales 514.43M
FCF (ttm) -18.97M
Book/sh 7.25
Cash/sh 42.40
Employees 667
Insider 10d —
IPO Jun 12, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -13.33
PEG —
P/S 0.16
P/B 1.07
P/C —
EV/EBITDA 7.19
EV/Sales -0.62
Quick Ratio 2.71
Current Ratio 3.05
Debt/Eq 9.85
LT Debt/Eq —
EPS (ttm) -0.83
EPS next Y -0.58
EPS Growth —
Revenue Growth -18.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-05-30
Earnings (prior) 2023-05-30
ROA -4.45%
ROE -10.90%
ROIC —
Gross Margin 74.55%
Oper. Margin -17.46%
Profit Margin -11.53%
Shs Outstand 8.81M
Shs Float 4.06M
Insider Own 4.01%
Instit Own 46.71%
Short Float 0.50%
Short Ratio 2.01
Short Interest 35.66K
52W High 41.72
vs 52W High -81.47%
52W Low 3.06
vs 52W Low 152.61%
Beta 1.32
Impl. Vol. —
Rel Volume 1.39
Avg Volume 27.94K
Volume 38.95K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $7.25
Price $7.73
Change 6.62%
About

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$7.73
Latest analyst target
3. DCF / Fair value
$-38.74
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.73
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2021-07-14 init CICC — → Outperform $40
2020-07-13 init B of A Securities — → Buy $32
2020-07-07 init Cowen & Co. — → Outperform —
News
RSS: Latest BNR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 HAN YUSHENG Director — 314,870 $17.36 $5,466,143
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
539.57
+4.60%
515.82
-4.02%
537.43
-4.58%
563.24
Operating Revenue
539.57
+4.60%
515.82
-4.02%
537.43
-4.58%
563.24
Cost Of Revenue
136.65
-10.93%
153.42
-11.93%
174.21
-4.91%
183.20
Reconciled Cost Of Revenue
136.65
-10.93%
153.42
-11.93%
174.21
-4.91%
183.20
Gross Profit
402.91
+11.18%
362.40
-0.23%
363.23
-4.42%
380.04
Operating Expense
457.76
-33.16%
684.83
-33.68%
1,032.55
-24.10%
1,360.45
Research And Development
166.49
-28.32%
232.29
-33.06%
347.02
-17.74%
421.87
Selling General And Administration
291.26
-35.64%
452.54
-33.99%
685.53
-26.96%
938.58
Selling And Marketing Expense
165.18
-13.48%
190.90
-22.93%
247.71
-33.10%
370.29
General And Administrative Expense
126.09
-51.81%
261.64
-40.24%
437.82
-22.96%
568.28
Other Gand A
126.09
-51.81%
261.64
-40.24%
437.82
-22.96%
568.28
Total Expenses
594.41
-29.09%
838.25
-30.54%
1,206.76
-21.82%
1,543.64
Operating Income
-54.84
+82.99%
-322.43
+51.83%
-669.32
+31.73%
-980.41
Total Operating Income As Reported
-54.84
+84.66%
-357.56
+46.58%
-669.32
+31.73%
-980.41
EBITDA
-32.00
+88.91%
-288.54
+44.29%
-517.90
+39.52%
-856.31
Normalized EBITDA
-25.29
+90.02%
-253.31
+51.05%
-517.48
+39.68%
-857.86
Reconciled Depreciation
21.76
-58.31%
52.20
-60.87%
133.40
+7.50%
124.10
EBIT
-53.76
+84.22%
-340.74
+47.68%
-651.30
+33.57%
-980.41
Total Unusual Items
-6.71
+80.95%
-35.23
-8287.38%
-0.42
-127.11%
1.55
Total Unusual Items Excluding Goodwill
-6.71
+80.95%
-35.23
-8287.38%
-0.42
-127.11%
1.55
Special Income Charges
0.00
+100.00%
-35.13
0.00
0.00
Impairment Of Capital Assets
0.00
-100.00%
35.13
0.00
0.00
Net Income
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Pretax Income
-53.79
+84.21%
-340.74
+47.68%
-651.30
+32.80%
-969.25
Net Non Operating Interest Income Expense
8.02
-34.30%
12.21
-31.99%
17.96
+89.85%
9.46
Interest Expense Non Operating
0.03
0.00
0.00
—
Net Interest Income
8.02
-34.30%
12.21
-31.99%
17.96
+89.85%
9.46
Interest Expense
0.03
0.00
0.00
—
Interest Income Non Operating
8.05
-34.06%
12.21
-31.99%
17.96
+89.85%
9.46
Interest Income
8.05
-34.06%
12.21
-31.99%
17.96
+89.85%
9.46
Other Income Expense
-6.97
+77.17%
-30.52
-47789.06%
0.06
-96.24%
1.70
Other Non Operating Income Expenses
-0.26
-105.46%
4.71
+872.31%
0.48
+218.42%
0.15
Gain On Sale Of Security
-6.71
-6611.00%
-0.10
+76.19%
-0.42
-127.11%
1.55
Tax Provision
1.56
-73.56%
5.88
+146.44%
2.39
+20.30%
1.99
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-1.68
+80.95%
-8.81
-8287.38%
-0.10
-127.11%
0.39
Net Income Including Noncontrolling Interests
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Net Income From Continuing Operation Net Minority Interest
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Net Income From Continuing And Discontinued Operation
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Net Income Continuous Operations
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Normalized Income
-50.31
+84.29%
-320.21
+50.99%
-653.37
+32.81%
-972.39
Net Income Common Stockholders
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-5.20
+84.57%
-33.70
+47.18%
-63.80
+31.76%
-93.50
Basic EPS
-5.20
+84.57%
-33.70
+47.18%
-63.80
+31.76%
-93.50
Basic Average Shares
10.63
+3.27%
10.29
+0.53%
10.24
-1.46%
10.39
Diluted Average Shares
10.63
+3.27%
10.29
+0.53%
10.24
-1.46%
10.39
Diluted NI Availto Com Stockholders
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
820.38
-7.33%
885.30
-14.87%
1,040.00
-34.49%
1,587.47
Current Assets
738.59
-4.90%
776.62
-12.16%
884.10
-29.76%
1,258.76
Cash Cash Equivalents And Short Term Investments
478.39
-7.97%
519.85
-15.48%
615.10
-32.07%
905.45
Cash And Cash Equivalents
478.39
-7.97%
519.85
-15.48%
615.10
-32.07%
905.45
Other Short Term Investments
—
—
—
0.00
Receivables
192.75
+11.13%
173.45
+3.36%
167.81
-1.42%
170.23
Accounts Receivable
169.61
+11.58%
152.01
+19.83%
126.86
+15.37%
109.95
Gross Accounts Receivable
228.87
+15.66%
197.88
+19.74%
165.25
+8.10%
152.87
Allowance For Doubtful Accounts Receivable
-59.25
-29.19%
-45.87
-19.46%
-38.40
+10.53%
-42.91
Other Receivables
12.30
-11.22%
13.86
-39.09%
22.75
-45.52%
41.76
Taxes Receivable
10.77
+45.49%
7.40
-56.53%
17.03
-7.54%
18.42
Accrued Interest Receivable
0.07
-60.45%
0.18
-84.99%
1.18
+1044.66%
0.10
Loans Receivable
—
—
—
0.00
Inventory
48.58
-9.65%
53.76
-22.11%
69.02
-47.04%
130.32
Raw Materials
28.45
-13.35%
32.83
-23.13%
42.70
-51.16%
87.43
Work In Process
4.37
-33.91%
6.62
+25.85%
5.26
-30.69%
7.59
Finished Goods
15.76
+10.05%
14.32
-32.01%
21.06
-40.35%
35.31
Prepaid Assets
7.39
-58.90%
17.99
-38.50%
29.25
+29.33%
22.62
Current Deferred Assets
8.40
-5.22%
8.86
0.00
—
Restricted Cash
2.70
+16.56%
2.31
+1827.50%
0.12
-99.39%
19.82
Other Current Assets
0.38
-4.30%
0.40
-85.88%
2.80
-72.90%
10.33
Total Non Current Assets
81.79
-24.75%
108.69
-30.29%
155.91
-52.57%
328.70
Net PPE
73.87
-26.38%
100.34
-30.41%
144.20
-51.94%
300.03
Gross PPE
564.14
-3.02%
581.71
+6.10%
548.29
-5.03%
577.33
Accumulated Depreciation
-490.27
-1.85%
-481.37
-19.12%
-404.10
-45.73%
-277.30
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
288.81
+0.12%
288.46
-2.42%
295.63
+2.89%
287.31
Construction In Progress
0.63
+0.00%
0.63
+15.69%
0.55
-79.39%
2.66
Other Properties
87.67
-16.82%
105.39
+62.83%
64.73
-35.26%
99.98
Leases
187.03
-0.11%
187.22
-0.09%
187.39
+0.01%
187.38
Goodwill And Other Intangible Assets
0.28
-32.54%
0.42
-56.33%
0.96
-51.46%
1.99
Other Intangible Assets
0.28
-32.54%
0.42
-56.33%
0.96
-51.46%
1.99
Investments And Advances
—
0.00
-100.00%
0.34
-51.16%
0.69
Long Term Equity Investment
—
0.00
-100.00%
0.34
-51.16%
0.69
Other Non Current Assets
7.63
-3.71%
7.93
+55.78%
5.09
-75.64%
20.89
Total Liabilities Net Minority Interest
285.11
-6.36%
304.48
+12.11%
271.59
-36.71%
429.13
Current Liabilities
246.98
-7.26%
266.30
+1.11%
263.36
-35.99%
411.45
Payables And Accrued Expenses
109.11
+4.00%
104.91
+0.83%
104.05
-37.39%
166.20
Payables
57.13
+18.51%
48.20
+24.63%
38.68
-37.58%
61.97
Accounts Payable
40.74
+20.73%
33.75
+86.85%
18.06
-64.55%
50.95
Current Accrued Expenses
51.99
-8.33%
56.71
-13.25%
65.37
-37.28%
104.23
Pensionand Other Post Retirement Benefit Plans Current
—
—
0.00
-100.00%
38.97
Total Tax Payable
16.38
+13.31%
14.46
-29.88%
20.62
+87.02%
11.03
Current Debt And Capital Lease Obligation
16.96
-30.96%
24.57
+184.54%
8.63
-76.81%
37.24
Current Debt
0.20
—
—
—
Other Current Borrowings
0.20
—
—
—
Current Capital Lease Obligation
16.76
-31.77%
24.57
+184.54%
8.63
-76.81%
37.24
Current Deferred Liabilities
108.41
-8.50%
118.49
-10.06%
131.73
-11.85%
149.44
Current Deferred Revenue
108.41
-8.50%
118.49
-10.06%
131.73
-11.85%
149.44
Other Current Liabilities
12.49
-31.85%
18.33
-3.24%
18.95
-3.38%
19.61
Total Non Current Liabilities Net Minority Interest
38.13
-0.12%
38.18
+364.07%
8.23
-53.45%
17.68
Long Term Debt And Capital Lease Obligation
26.16
-5.75%
27.75
+652.14%
3.69
-72.77%
13.55
Long Term Debt
1.70
—
—
—
Long Term Capital Lease Obligation
24.46
-11.88%
27.75
+652.14%
3.69
-72.77%
13.55
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Other Non Current Liabilities
11.97
+14.87%
10.43
+129.78%
4.54
+10.01%
4.12
Stockholders Equity
535.26
-7.84%
580.83
-24.41%
768.41
-33.66%
1,158.34
Common Stock Equity
535.26
-7.84%
580.83
-24.41%
768.41
-33.66%
1,158.34
Capital Stock
0.14
-2.76%
0.14
+5.84%
0.14
-0.72%
0.14
Common Stock
0.14
-2.76%
0.14
+5.84%
0.14
-0.72%
0.14
Share Issued
108.21
-2.20%
110.64
+4.91%
105.46
-0.19%
105.67
Ordinary Shares Number
105.18
-2.26%
107.61
+5.05%
102.44
-0.20%
102.64
Treasury Shares Number
3.02
+0.00%
3.02
+0.00%
3.02
+0.00%
3.02
Additional Paid In Capital
5,010.06
+0.16%
5,002.26
+3.15%
4,849.34
+5.82%
4,582.79
Retained Earnings
-4,255.61
-1.32%
-4,200.26
-8.99%
-3,853.64
-20.43%
-3,199.95
Gains Losses Not Affecting Retained Earnings
-162.14
-2.59%
-158.05
+2.16%
-161.53
+2.53%
-165.72
Treasury Stock
57.19
-9.60%
63.26
-3.99%
65.90
+11.84%
58.92
Other Equity Adjustments
-162.14
-2.59%
-158.05
+2.16%
-161.53
+2.53%
-165.72
Total Equity Gross Minority Interest
535.26
-7.84%
580.83
-24.41%
768.41
-33.66%
1,158.34
Total Capitalization
536.96
-7.55%
580.83
-24.41%
768.41
-33.66%
1,158.34
Working Capital
491.61
-3.67%
510.32
-17.79%
620.73
-26.74%
847.31
Invested Capital
537.16
-7.52%
580.83
-24.41%
768.41
-33.66%
1,158.34
Total Debt
43.12
-17.59%
52.32
+324.55%
12.32
-75.73%
50.79
Capital Lease Obligations
41.22
-21.22%
52.32
+324.55%
12.32
-75.73%
50.79
Net Tangible Assets
534.98
-7.83%
580.41
-24.37%
767.45
-33.63%
1,156.36
Tangible Book Value
534.98
-7.83%
580.41
-24.37%
767.45
-33.63%
1,156.36
Duefrom Related Parties Current
—
—
—
—
Interest Payable
—
—
—
0.00
Non Current Note Receivables
—
0.00
-100.00%
5.32
+4.21%
5.11
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-28.44
+69.17%
-92.26
+63.93%
-255.78
+44.01%
-456.81
Cash Flow From Continuing Operating Activities
-28.44
+69.17%
-92.26
+63.93%
-255.78
+44.01%
-456.81
Net Income From Continuing Operations
-55.35
+84.03%
-346.63
+46.97%
-653.69
+32.69%
-971.23
Depreciation Amortization Depletion
21.76
-58.31%
52.20
-60.87%
133.40
+7.50%
124.10
Depreciation
—
51.39
-60.91%
131.45
+8.87%
120.75
Amortization Cash Flow
—
0.81
-58.26%
1.95
-41.83%
3.35
Depreciation And Amortization
21.76
-58.31%
52.20
-60.87%
133.40
+7.50%
124.10
Amortization Of Intangibles
—
0.81
-58.26%
1.95
-41.83%
3.35
Other Non Cash Items
24.44
-7.25%
26.35
-25.12%
35.18
-4.84%
36.97
Stock Based Compensation
13.88
-91.08%
155.62
-40.31%
260.72
-20.22%
326.78
Provisionand Write Offof Assets
20.34
+48.03%
13.74
-29.91%
19.61
-45.72%
36.12
Asset Impairment Charge
0.00
-100.00%
35.37
0.00
0.00
Operating Gains Losses
-0.20
-108.90%
2.29
+67.49%
1.37
-20.04%
1.71
Unrealized Gain Loss On Investment Securities
6.08
+14.27%
5.32
+2574.42%
-0.21
-104.76%
-0.10
Gain Loss On Sale Of PPE
-0.20
-109.27%
2.20
+118.25%
1.01
-28.91%
1.42
Change In Working Capital
-59.39
-62.56%
-36.53
+29.96%
-52.16
-367.40%
-11.16
Change In Receivables
-33.23
-23.98%
-26.80
-63.44%
-16.40
+61.11%
-42.16
Changes In Account Receivables
-30.98
+5.03%
-32.63
-163.41%
-12.39
+42.40%
-21.50
Change In Inventory
2.50
-0.40%
2.51
-95.62%
57.28
+364.51%
-21.65
Change In Prepaid Assets
6.45
-66.56%
19.28
+56.09%
12.35
-63.58%
33.92
Change In Payables And Accrued Expense
0.32
-96.88%
10.20
+120.26%
-50.37
-200.15%
50.29
Change In Accrued Expense
-6.86
+21.06%
-8.69
+54.86%
-19.25
-157.18%
33.66
Change In Payable
7.18
-62.02%
18.89
+160.70%
-31.12
-287.13%
16.63
Change In Account Payable
7.18
-62.02%
18.89
+160.70%
-31.12
-287.13%
16.63
Change In Other Working Capital
-10.30
+26.96%
-14.11
+18.33%
-17.27
-376.13%
6.26
Change In Other Current Liabilities
-25.12
+9.05%
-27.62
+26.83%
-37.74
+0.18%
-37.81
Investing Cash Flow
-4.39
+0.48%
-4.41
+52.56%
-9.30
-24.61%
-7.46
Cash Flow From Continuing Investing Activities
-4.39
+0.48%
-4.41
+52.56%
-9.30
-24.61%
-7.46
Net PPE Purchase And Sale
-4.39
-13.93%
-3.85
+51.95%
-8.02
+88.18%
-67.88
Purchase Of PPE
-5.25
+3.14%
-5.42
+33.13%
-8.10
+88.47%
-70.29
Sale Of PPE
0.86
-45.18%
1.56
+1763.10%
0.08
-96.52%
2.41
Capital Expenditure
-5.25
+12.18%
-5.98
+36.31%
-9.38
+86.68%
-70.47
Net Investment Purchase And Sale
—
0.00
0.00
-100.00%
65.60
Purchase Of Investment
—
—
0.00
0.00
Sale Of Investment
—
0.00
0.00
-100.00%
65.60
Net Intangibles Purchase And Sale
0.00
+100.00%
-0.56
+56.41%
-1.28
-591.89%
-0.18
Purchase Of Intangibles
0.00
+100.00%
-0.56
+56.41%
-1.28
-591.89%
-0.18
Net Other Investing Changes
—
—
—
-5.00
Financing Cash Flow
1.90
+2738.89%
-0.07
+99.85%
-48.83
+43.38%
-86.24
Cash Flow From Continuing Financing Activities
1.90
+2738.89%
-0.07
+99.85%
-48.83
+43.38%
-86.24
Net Issuance Payments Of Debt
1.90
0.00
0.00
+100.00%
-2.37
Issuance Of Debt
2.00
0.00
0.00
0.00
Repayment Of Debt
-0.10
0.00
0.00
+100.00%
-2.37
Long Term Debt Issuance
2.00
0.00
0.00
0.00
Long Term Debt Payments
-0.10
0.00
0.00
0.00
Net Long Term Debt Issuance
1.90
0.00
0.00
0.00
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
0.00
0.00
+100.00%
-2.37
Net Short Term Debt Issuance
—
0.00
0.00
+100.00%
-2.37
Net Common Stock Issuance
0.00
+100.00%
-0.07
+98.97%
-6.98
+90.29%
-71.83
Common Stock Payments
0.00
+100.00%
-0.07
+98.97%
-6.98
+90.29%
-71.83
Repurchase Of Capital Stock
0.00
+100.00%
-0.07
+98.97%
-6.98
+90.29%
-71.83
Proceeds From Stock Option Exercised
0.00
0.00
+100.00%
-41.85
-247.78%
-12.04
Net Other Financing Charges
—
—
—
-12.04
Changes In Cash
-30.93
+68.03%
-96.75
+69.18%
-313.92
+42.98%
-550.51
Effect Of Exchange Rate Changes
-10.14
-374.72%
3.69
-4.45%
3.86
-89.46%
36.67
Beginning Cash Position
522.16
-15.13%
615.22
-33.51%
925.27
-35.71%
1,439.11
End Cash Position
481.09
-7.87%
522.16
-15.13%
615.22
-33.51%
925.27
Free Cash Flow
-33.69
+65.70%
-98.24
+62.95%
-265.17
+49.71%
-527.28
Interest Paid Supplemental Data
0.03
0.00
0.00
-100.00%
0.88
Income Tax Paid Supplemental Data
0.00
0.00
0.00
-100.00%
0.10
Common Stock Issuance
—
—
—
0.00
Earnings Losses From Equity Investments
0.00
-100.00%
0.09
-74.24%
0.36
+22.79%
0.29
Issuance Of Capital Stock
—
—
—
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Payments
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category